HC Wainwright Comments on Nyxoah’s Q1 Earnings (NASDAQ:NYXH)

Nyxoah S.A. (NASDAQ:NYXH) – Research analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for shares of Nyxoah in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will earn ($0.48) per share for the quarter, up from their previous forecast of ($0.50). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Nyxoah’s Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The business had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%.

Separately, Stifel Nicolaus decreased their target price on Nyxoah from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 14th.

Nyxoah Stock Performance

NASDAQ NYXH opened at $7.65 on Friday. The company’s fifty day moving average is $10.35 and its two-hundred day moving average is $9.34. Nyxoah has a 52-week low of $6.76 and a 52-week high of $13.50. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95. The firm has a market capitalization of $260.56 million, a price-to-earnings ratio of -4.09 and a beta of 1.42.

Institutional Investors Weigh In On Nyxoah

A number of institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP acquired a new position in shares of Nyxoah in the 4th quarter valued at $23,394,000. Renaissance Technologies LLC acquired a new position in Nyxoah in the fourth quarter worth about $187,000. Kovack Advisors Inc. lifted its stake in Nyxoah by 100.0% during the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock worth $160,000 after purchasing an additional 10,000 shares during the period. Geode Capital Management LLC boosted its holdings in Nyxoah by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after purchasing an additional 2,774 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in Nyxoah during the fourth quarter valued at approximately $135,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.